The Association Between Chlorhexidine Bathing and Central Line-Associated Infections in Medical Intensive Care Units

Central Line-associated Bloodstream Infection (CLABSI) Clinical Trial

Official title:

The Association Between Chlorhexidine Bathing Every Other Day and Central Line-Associated Infections in Medical Intensive Care Units: An Observational Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05919966
• Other study ID #: 202302031RINC
• Status: Completed
• Start date: April 12, 2023
• Est. completion date: May 30, 2023

Study information

• Verified date: April 2023
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We conducted a retrospective observational cohort study assessing the relationship between regular bathing using 2% CHG wipes every other day and the occurrence of central line-associated infections (CLABSI) in patients within the medical intensive care unit (MICU).

Description:

This study defined the post-intervention period as July 1, 2017, to June 30, 2022. During this period, one of the three medical intensive care units (MICUs) in NTUH implemented chlorhexidine gluconate (CHG) bathing as part of their daily care routine (CHG group). This decision was made in response to a higher incidence rate of vancomycin-resistant Enterococcus (VRE) bacteremia observed in that particular MICU during the preceding six months (pre-intervention period: January 1, 2017, to June 30, 2017), compared to the other two MICUs. The remaining two MICUs continued to provide usual care, which involved bathing patients with towels soaked in water and soap on a daily basis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6930
• Est. completion date: May 30, 2023
• Est. primary completion date: April 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• all patients who were admitted to the MICU between January 2017 and June 2022

Exclusion Criteria:

• patients aged under 18 years old

Related Conditions & MeSH terms

• Central Line-associated Bloodstream Infection (CLABSI)
• Communicable Diseases
• Infections
• Sepsis

Intervention

Other:
• Chlorhexidine bathing
The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	central line-associated bloodstream infections	the incidence rate of intensive care unit acquired central line-associated bloodstream infections	Will be surveyed retrospectively through the study period (January 2017 to June 2022)
Primary	multidrug-resistant organisms bacteremia	the incidence of CLABSIs with blood cultures positive for multidrug-resistant organisms	Will be surveyed retrospectively through the study period (January 2017 to June 2022)
Secondary	ICU length of stay	the total duration of the patient's ICU stay (days)	Will be surveyed retrospectively through the study period (January 2017 to June 2022)
Secondary	hospital length of stay	the total duration of the patient's hospital stay (days)	Will be surveyed retrospectively through the study period (January 2017 to June 2022)
Secondary	ICU mortality	whether the patient has died during their stay in the ICU	Will be surveyed retrospectively through the study period (January 2017 to June 2022)
Secondary	hospital mortality	whether the patient has died during their stay in the hospital	Will be surveyed retrospectively through the study period (January 2017 to June 2022)